Gary Ulaner

Clinical Professor of Radiology and Translational Genomics (Part Time)

Image of Gary Ulaner
Is this your profile? Click to edit

Overview

Dr. Gary Ulaner is the James & Pamela Muzzy Endowed Chair of Molecular Imaging and Therapy (MIT) at the Hoag Family Cancer Institute and Professor of Radiology and Translational Genomics at the University of Southern California.

Gary has been the principal investigator of prospective clinical trials for six novel PET radiotracers for patients with breast cancer, prostate cancer and myeloma, funded by two National Institutes of Health R01s, as well as grants from the Department of Defense (DoD) Breast Cancer Research Programs, Susan G. Komen Foundation, and Rising Tide Foundation. His clinical trials emphasize targeted imaging to guide targeted therapy of cancer, particularly ER, HER2, PSMA and CD38 targeted PET imaging.

Gary in on the editorial board of 4 leading radiology journals, authored the text “Fundamentals of Oncologic PET/CT”, and is on the scientific advisory boards of ImaginAb, GE Healthcare, and the Lobular Breast Cancer Alliance.

Gary currently lives in Irvine, California, with his wife, Alena, son, Ilya, and daughter, Anabel. He met his wife swing dancing, and they are still dancing today, albeit with less frequency.

Awards

  • James and Pamela Muzzy Endowed Chair, 2021
  • American College of Nuclear Medicine – President’s Award, 2019
  • First Hal O’Brien Rising Star Award, Society of Nuclear Medicine and Molecular Imaging (SNMMI), 2018
  • Jon Shevell Award from the Susan Komen Foundation, 2017
  • Elected Fellow, American College of Nuclear Medicine, 2017
  • Clinical Nuclear Medicine Editor’s Award, 2017
  • Jon Shevell Young Scientist Scholarship, Susan Komen Foundation, 2016
  • Radiology Editor’s Recognition Award with Special Distinction, 2016
  • SNMMI Best Breast Cancer Research Abstract, 2016
  • SNMMI first place prize in Basic Science, 2016
  • MSKCC Department of Radiology, Excellence in Teaching Award, 2016
  • Weill Cornell Department of Radiology, Best Teacher, 2016
  • Radiology Editor’s Recognition Award with Special Distinction, 2015
  • Radiographics Educational Design Award, 2015
  • Department of Defense Breakthrough Award, 2014
  • Susan Komen for the Cure Career Catalyst Award, 2012
  • RSNA Excellence Award for Research, 2011
  • Resident of the Year, University of Southern California, 2009
  • RSNA Roentgen Resident Research Award, 2005
  • National Institutes of Health Post-Doctoral Fellowship, 2001
  • National Institutes of Health Medical Scientist Training Program, 1997
  • National Institutes of Health Cancer Biology Pre-Doctoral Fellowship, 1994

Publications

  • Value of MRI in evaluating urachal carcinoma: A single center retrospective studyUrol Oncol. 2022 07; 40(7):345. e9-345. e17. . View in PubMed
  • Prospective investigation of amino acid transport and PSMA-targeted positron emission tomography for metastatic lobular breast carcinoma Eur J Nucl Med Mol Imaging. 2024 Jul 08. . View in PubMed
  • 111 In-Pentetreotide-Guided Radiosurgery for Intraoperative Localization of Retroperitoneal Nodal Metastasis in a Patient With Ileal Neuroendocrine Tumor Clin Nucl Med. 2024 Jul 01; 49(7):695-697. . View in PubMed
  • Interreader and Intrareader Reproducibility of 18F-Flotufolastat Image Interpretation in Patients with Newly Diagnosed or Recurrent Prostate Cancer: Data from Two Phase 3 Prospective Multicenter Studies J Nucl Med. 2024 Jun 13. . View in PubMed
  • ACR Appropriateness Criteria® Imaging of Invasive Breast Cancer J Am Coll Radiol. 2024 Jun; 21(6S):S168-S202. . View in PubMed
  • ACR Appropriateness Criteria® Female Breast Cancer Screening: 2023 Update J Am Coll Radiol. 2024 Jun; 21(6S):S126-S143. . View in PubMed
  • HER2-targeted PET for Patients with Breast Cancer: Scintillating Data Radiology. 2024 Jun; 311(3):e240814. . View in PubMed
  • Joint EANM-SNMMI guideline on the role of 2-[18F]FDG PET/CT in no special type breast cancer : (endorsed by the ACR, ESSO, ESTRO, EUSOBI/ESR, and EUSOMA) Eur J Nucl Med Mol Imaging. 2024 May 14. . View in PubMed
  • Joint EANM-SNMMI guidelines on the role of 2-[18F]FDG PET/CT in no special type breast cancer: differences and agreements with European and American guidelines Eur J Nucl Med Mol Imaging. 2024 May 02. . View in PubMed
  • Negative 18F-Piflufolastat PET/CT, But Positive 18F-Fluciclovine PET/CT, in a Patient With Biochemically Recurrent Prostate Cancer Clin Nucl Med. 2024 May 02. . View in PubMed
  • Mixed histiocytic neoplasms: A multicentre series revealing diverse somatic mutations and responses to targeted therapy Br J Haematol. 2024 Apr 12. . View in PubMed
  • Quarter-Century Transformation of Oncology: Positron Emission Tomography for Patients with Breast Cancer PET Clin. 2024 Apr; 19(2):147-162. . View in PubMed
  • First-in-Human Evaluation of Site-Specifically Labeled 89Zr-Pertuzumab in Patients with HER2-Positive Breast Cancer J Nucl Med. 2024 Mar 01; 65(3):386-393. . View in PubMed
  • Women’s Health Update: Growing Role of PET for Patients with Breast Cancer Semin Nucl Med. 2024 Mar; 54(2):247-255. . View in PubMed
  • Summary: SNMMI Procedure Standard/EANM Practice Guideline for Estrogen Receptor Imaging of Patients with Breast Cancer Using 16a-[18F]Fluoro-17ß-Estradiol PET J Nucl Med. 2024 Feb 01; 65(2):221-223. . View in PubMed
  • Fluorine-18-Labeled Fluoroestradiol PET/CT: Current Status, Gaps in Knowledge, and Controversies-AJR Expert Panel Narrative Review AJR Am J Roentgenol. 2023 Dec 20. . View in PubMed
  • Estrogen Receptor-Targeted and Progesterone Receptor-Targeted PET for Patients with Breast Cancer PET Clin. 2023 Oct; 18(4):531-542. . View in PubMed
  • Evaluation of Treatment Response in Patients with Breast Cancer PET Clin. 2023 Oct; 18(4):517-530. . View in PubMed
  • Other Novel PET Radiotracers for Breast Cancer PET Clin. 2023 Oct; 18(4):557-566. . View in PubMed
  • Metabolic Positron Emission Tomography in Breast Cancer PET Clin. 2023 Oct; 18(4):473-485. . View in PubMed
  • Human Epidermal Growth Factor Receptor 2/Human Epidermal Growth Factor Receptor 3 PET Imaging: Challenges and Opportunities PET Clin. 2023 Oct; 18(4):543-555. . View in PubMed
  • Molecular Classification of Breast Cancer PET Clin. 2023 Oct; 18(4):441-458. . View in PubMed
  • Value of subspecialist second opinion reads of 18 F-FDG PET-CT examinations for patients with breast cancer Nucl Med Commun. 2023 Sep 01; 44(9):825-829. . View in PubMed
  • Breast Cancer and Physiologic Avidity From Breast Feeding on FDG PET/CT Clin Nucl Med. 2023 May 01; 48(5):420-421. . View in PubMed
  • A Discordant Pattern of Uptake on 68 Ga-PSMA PET/CT Versus 18 F-Fluciclovine PET/CT in Radiation-Induced Hepatitis : Implications for Early Postradiotherapy Imaging-Based Response Assessment Clin Nucl Med. 2023 Apr 01; 48(4):e202-e203. . View in PubMed
  • ACR Appropriateness Criteria® Breast Implant Evaluation: 2023 Update J Am Coll Radiol. 2023 11; 20(11S):S329-S350. . View in PubMed
  • Breast Cancer: Advances in Molecular Imaging PET Clin. 2023 10; 18(4):xiii-xiv. . View in PubMed
  • CSF1R inhibition for histiocytic neoplasm with CBL mutations refractory to MEK1/2 inhibition Leukemia. 2023 08; 37(8):1737-1740. . View in PubMed
  • ACR Appropriateness Criteria® Palpable Breast Masses: 2022 Update J Am Coll Radiol. 2023 05; 20(5S):S146-S163. . View in PubMed
  • ACR Appropriateness Criteria® Monitoring Response to Neoadjuvant Systemic Therapy for Breast Cancer: 2022 Update J Am Coll Radiol. 2023 05; 20(5S):S125-S145. . View in PubMed
  • Summary: Appropriate Use Criteria for Estrogen Receptor-Targeted PET Imaging with 16a-18F-Fluoro-17ß-Fluoroestradiol J Nucl Med. 2023 03; 64(3):351-354. . View in PubMed
  • False-Positive for Pulmonary Emboli on Ventilation/Perfusion Scan Due to Improper Patient Positioning During Tracer Administration Clin Nucl Med. 2023 Jan 01; 48(1):95-97. . View in PubMed
  • Detection of Biochemically Recurrent Prostate Cancer with [18F]DCFPyL PET/CT: An Updated Systematic Review and Meta-Analysis with a Focus on Correlations with Serum Prostate-Specific Antigen Parameters Tomography. 2023 08 15; 9(4):1504-1514. . View in PubMed
  • Successful treatment of non-Langerhans cell histiocytosis with the MEK inhibitor trametinib: a multicenter analysis Blood Adv. 2023 08 08; 7(15):3984-3992. . View in PubMed
  • A Tale of 3 Tracers: Contrasting Uptake Patterns of 18F-Fluciclovine, 68Ga-PSMA, and 18F-FDG in the Uterus and Adnexa Clin Nucl Med. 2023 Jan 01; 48(1):e26-e27. . View in PubMed
  • High-resolution and high-sensitivity PET for quantitative molecular imaging of the monoaminergic nuclei: A GATE simulation study Med Phys. 2022 Jul; 49(7):4430-4444. . View in PubMed
  • ACR Appropriateness Criteria® Imaging After Breast Surgery J Am Coll Radiol. 2022 11; 19(11S):S341-S356. . View in PubMed
  • ACR Appropriateness Criteria® Evaluation of Nipple Discharge: 2022 Update J Am Coll Radiol. 2022 11; 19(11S):S304-S318. . View in PubMed
  • 18F-DCFPyL PET/CT for Initially Diagnosed and Biochemically Recurrent Prostate Cancer: Prospective Trial with Pathologic Confirmation Radiology. 2022 11; 305(2):419-428. . View in PubMed
  • 16a-18F-fluoro-17ß-Fluoroestradiol (FES): Clinical Applications for Patients With Breast Cancer Semin Nucl Med. 2022 09; 52(5):574-583. . View in PubMed
  • CD8-Targeted PET Imaging of Tumor-Infiltrating T Cells in Patients with Cancer: A Phase I First-in-Humans Study of 89Zr-Df-IAB22M2C, a Radiolabeled Anti-CD8 Minibody J Nucl Med. 2022 05; 63(5):720-726. . View in PubMed
  • Phase II Trial of Imatinib Plus Binimetinib in Patients With Treatment-Naive Advanced Gastrointestinal Stromal Tumor J Clin Oncol. 2022 03 20; 40(9):997-1008. . View in PubMed
  • AMEERA-1 phase 1/2 study of amcenestrant, SAR439859, in postmenopausal women with ER-positive/HER2-negative advanced breast cancer Nat Commun. 2022 07 15; 13(1):4116. . View in PubMed
  • 18F-FDG-Avid Lymph Nodes After COVID-19 Vaccination on 18F-FDG PET/CT Clin Nucl Med. 2021 May 01; 46(5):433-434. . View in PubMed
  • Malignant perivascular epithelioid cell tumor of the ileum on 18F-fluorodeoxyglucose positron emission tomography/ computed tomography with pathological correlation World J Nucl Med. 2021 Apr-Jun; 20(2):208-210. . View in PubMed
  • Author Correction: Accelerated single cell seeding in relapsed multiple myeloma Nat Commun. 2021 Jan 20; 12(1):591. . View in PubMed
  • Improved image reconstruction of 89Zr-immunoPET studies using a Bayesian penalized likelihood reconstruction algorithm EJNMMI Phys. 2021 Jan 19; 8(1):6. . View in PubMed
  • 18F-FDG PET/CT versus anatomic imaging for evaluating disease extent and clinical trial eligibility in Erdheim-Chester disease: results from 50 patients in a registry study Eur J Nucl Med Mol Imaging. 2021 04; 48(4):1154-1165. . View in PubMed
  • Noninvasive Monitoring of Mantle Cell Lymphoma by Immunoglobulin Gene Next-Generation Sequencing in a Phase 2 Study of Sequential Chemoradioimmunotherapy Followed by Autologous Stem-Cell RescueClin Lymphoma Myeloma Leuk. 2021 04; 21(4):230-237. e12. . View in PubMed
  • Head-to-Head Evaluation of 18F-FES and 18F-FDG PET/CT in Metastatic Invasive Lobular Breast Cancer J Nucl Med. 2021 03; 62(3):326-331. . View in PubMed
  • Diffusion and Perfusion MRI Predicts Response Preceding and Shortly After Radiosurgery to Brain Metastases: A Pilot Study J Neuroimaging. 2021 03; 31(2):317-323. . View in PubMed
  • Defining the undetectable: The current landscape of minimal residual disease assessment in multiple myeloma and goals for future clarity Blood Rev. 2021 03; 46:100732. . View in PubMed
  • Mars Shot for Nuclear Medicine, Molecular Imaging, and Molecularly Targeted Radiopharmaceutical Therapy J Nucl Med. 2021 01; 62(1):6-14. . View in PubMed
  • Intra-arterial Melphalan for Neurologic Non-Langerhans Cell Histiocytosis Neurology. 2021 06 08; 96(23):1091-1093. . View in PubMed
  • Clinical Utility of 18F-FDG PET/CT for Staging and Treatment Planning in Urachal Adenocarcinoma J Nucl Med. 2021 05 10; 62(5):643-647. . View in PubMed
  • Dual PET Imaging in Bronchial Neuroendocrine Neoplasms: The NETPET Score as a Prognostic Biomarker J Nucl Med. 2021 09 01; 62(9):1278-1284. . View in PubMed
  • Minimal Residual Disease in Myeloma: Application for Clinical Care and New Drug Registration Clin Cancer Res. 2021 10 01; 27(19):5195-5212. . View in PubMed
  • Letter to the Editor: PET/CT in Locally Advanced Breast Cancer: Time for a Guideline Change? J Natl Compr Canc Netw. 2021 08 01; 19(8):xxx.. View in PubMed
  • Evidence-Based Best Practices: 18F-FDG PET Staging of Newly Diagnosed Breast Cancer Clin Nucl Med. 2021 07 01; 46(7):569-570. . View in PubMed
  • 18F-FDG PET/CT Helps Differentiate Peripheral Nerve Myeloid Sarcoma From a Presumed Benign Nerve Sheath Tumor Clin Nucl Med. 2020 Dec; 45(12):989-991. . View in PubMed
  • The Contribution of MicroRNAs to the Inflammatory and Neoplastic Characteristics of Erdheim-Chester Disease Cancers (Basel). 2020 Nov 03; 12(11). . View in PubMed
  • Extramedullary Myeloma of the Uterus on 18F-FDG PET/CT: A Rare Manifestation of Multiple Myeloma Clin Nucl Med. 2020 Nov; 45(11):873-875. . View in PubMed
  • Acute Aortic Dissection Initially Suspected on 18F-FDG PET/CT Clin Nucl Med. 2020 Oct; 45(10):819-820. . View in PubMed
  • Mucinous urachal adenocarcinoma: A potential nonfluorodeoxyglucose-avid pitfall on 18fluorine-fluorodeoxyglucose positron emission tomography/computed tomography World J Nucl Med. 2020 Oct-Dec; 19(4):432-434. . View in PubMed
  • Laboratory-Proven Asymptomatic SARS-CoV-2 (COVID-19) Infection on 18F-FDG PET/CT Clin Nucl Med. 2020 Aug; 45(8):654-655. . View in PubMed
  • Rosai-Dorfman Disease-Utility of 18F-FDG PET/CT for Initial Evaluation and Follow-up Clin Nucl Med. 2020 Jun; 45(6):e260-e266. . View in PubMed
  • The QIBA Profile for FDG PET/CT: Improving the Value of PET Radiology. 2020 Mar; 294(3):658-659. . View in PubMed
  • Identification of HER2-Positive Metastases in Patients with HER2-Negative Primary Breast Cancer by Using HER2-targeted 89Zr-Pertuzumab PET/CT Radiology. 2020 08; 296(2):370-378. . View in PubMed
  • CD38-targeted Immuno-PET of Multiple Myeloma: From Xenograft Models to First-in-Human Imaging Radiology. 2020 06; 295(3):606-615. . View in PubMed
  • HER2-Mediated Internalization of Cytotoxic Agents in ERBB2 Amplified or Mutant Lung Cancers Cancer Discov. 2020 05; 10(5):674-687. . View in PubMed
  • Current and potential applications of positron emission tomography for multiple myeloma and plasma cell disorders Best Pract Res Clin Haematol. 2020 03; 33(1):101148. . View in PubMed
  • Efficacy and Determinants of Response to HER Kinase Inhibition in HER2-Mutant Metastatic Breast Cancer Cancer Discov. 2020 02; 10(2):198-213. . View in PubMed
  • Neurologic and oncologic features of Erdheim-Chester disease: a 30-patient series Neuro Oncol. 2020 07 07; 22(7):979-992. . View in PubMed
  • Accelerated single cell seeding in relapsed multiple myeloma Nat Commun. 2020 07 17; 11(1):3617. . View in PubMed
  • Theranostics. 2020; 10(4):1746-1757. . View in PubMed
  • Patient Repositioning Reveals a Malignant Pleura Effusion Initially Mistaken as a Bone Metastasis on 18FDG PET/CT Clin Nucl Med. 2019 Dec; 44(12):969-970. . View in PubMed
  • ACR Appropriateness Criteria® Stage I Breast Cancer: Initial Workup and Surveillance for Local Recurrence and Distant Metastases in Asymptomatic Women J Am Coll Radiol. 2019 Nov; 16(11S):S428-S439. . View in PubMed
  • Focal Immunotherapy-Induced Pancreatitis Mimicking Metastasis on FDG PET/CT Clin Nucl Med. 2019 Oct; 44(10):836-837. . View in PubMed
  • Hepatocellular Carcinoma Mimicking Neuroendocrine Tumor Metastasis on 68Ga-DOTATATE PET/CT Clin Nucl Med. 2019 Apr; 44(4):330-331. . View in PubMed
  • Correction: 18F-Fluoroestradiol PET/CT Measurement of Estrogen Receptor Suppression during a Phase I Trial of the Novel Estrogen Receptor-Targeted Therapeutic GDC-0810: Using an Imaging Biomarker to Guide Drug Dosage in Subsequent Trials Clin Cancer Res. 2019 Feb 15; 25(4):1435. . View in PubMed
  • Activating mutations in CSF1R and additional receptor tyrosine kinases in histiocytic neoplasms Nat Med. 2019 12; 25(12):1839-1842. . View in PubMed
  • PET/CT for Patients With Breast Cancer: Where Is the Clinical Impact? AJR Am J Roentgenol. 2019 08; 213(2):254-265.. View in PubMed
  • 18F-FDG PET/CT for Systemic Staging of Newly Diagnosed Breast Cancer in Men J Nucl Med. 2019 04; 60(4):472-477. . View in PubMed
  • Factors Affecting Oncologic Outcomes of 90Y Radioembolization of Heavily Pre-Treated Patients With Colon Cancer Liver Metastases Clin Colorectal Cancer. 2019 03; 18(1):8-18. . View in PubMed
  • Efficacy of MEK inhibition in patients with histiocytic neoplasms Nature. 2019 03; 567(7749):521-524. . View in PubMed
  • Author Correction: HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2019 02; 566(7745):E11-E12. . View in PubMed
  • Detection of recurrent pancreatic cancer: value of second-opinion interpretations of cross-sectional images by subspecialized radiologists Abdom Radiol (NY). 2019 02; 44(2):586-592. . View in PubMed
  • Efficacy and Safety of Gemcitabine With Trastuzumab and Pertuzumab After Prior Pertuzumab-Based Therapy Among Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: A Phase 2 Clinical Trial JAMA Netw Open. 2019 11 01; 2(11):e1916211. . View in PubMed
  • Impact of FDG PET Imaging for Expanding Patient Eligibility and Measuring Treatment Response in a Genome-Driven Basket Trial of the Pan-HER Kinase Inhibitor, Neratinib Clin Cancer Res. 2019 12 15; 25(24):7381-7387. . View in PubMed
  • ACR Appropriateness Criteria® Evaluation of the Symptomatic Male Breast J Am Coll Radiol. 2018 Nov; 15(11S):S313-S320. . View in PubMed
  • 90Y Resin Microspheres Radioembolization for Colon Cancer Liver Metastases Using Full-Strength Contrast Material Cardiovasc Intervent Radiol. 2018 Sep; 41(9):1419-1427. . View in PubMed
  • Mazabraud’s Syndrome Mimicking Metastases on FDG PET/CT in a Patient With Colon Cancer Clin Nucl Med. 2018 Aug; 43(8):625-626. . View in PubMed
  • Diagnostic Role of Fluorodeoxyglucose PET in Breast Cancer: A History to Current Application PET Clin. 2018 Jul; 13(3):355-361. . View in PubMed
  • Molecular Classification of Breast Cancer PET Clin. 2018 Jul; 13(3):325-338. . View in PubMed
  • Clinical Potential of Human Epidermal Growth Factor Receptor 2 and Human Epidermal Growth Factor Receptor 3 Imaging in Breast Cancer PET Clin. 2018 Jul; 13(3):423-435. . View in PubMed
  • Amino Acid Metabolism as a Target for Breast Cancer Imaging PET Clin. 2018 Jul; 13(3):437-444. . View in PubMed
  • Adalimumab-Induced Epstein-Barr Virus-Related Lymphoproliferative Disorder on FDG PET/CT Clin Nucl Med. 2018 May; 43(5):344-345. . View in PubMed
  • Vemurafenib for BRAF V600-Mutant Erdheim-Chester Disease and Langerhans Cell Histiocytosis: Analysis of Data From the Histology-Independent, Phase 2, Open-label VE-BASKET Study JAMA Oncol. 2018 Mar 01; 4(3):384-388. . View in PubMed
  • Uses and Opportunities for Molecular Imaging in Patients with Breast Cancer PET Clin. 2018 07; 13(3):xi-xii. . View in PubMed
  • First-in-Human Human Epidermal Growth Factor Receptor 2-Targeted Imaging Using 89Zr-Pertuzumab PET/CT: Dosimetry and Clinical Application in Patients with Breast Cancer J Nucl Med. 2018 06; 59(6):900-906. . View in PubMed
  • Single-agent dabrafenib for BRAFV600E-mutated histiocytosis Haematologica. 2018 04; 103(4):e177-e180. . View in PubMed
  • Long-Half-Life 89Zr-Labeled Radiotracers Can Guide Percutaneous Biopsy Within the PET/CT Suite Without Reinjection of Radiotracer J Nucl Med. 2018 03; 59(3):399-402. . View in PubMed
  • HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018 02 08; 554(7691):189-194. . View in PubMed
  • Trends in oncologic hybrid imaging Eur J Hybrid Imaging. 2018; 2(1):1. . View in PubMed
  • Ado-Trastuzumab Emtansine for Patients With HER2-Mutant Lung Cancers: Results From a Phase II Basket Trial J Clin Oncol. 2018 08 20; 36(24):2532-2537. . View in PubMed
  • 89Zr-Trastuzumab PET/CT for Detection of Human Epidermal Growth Factor Receptor 2-Positive Metastases in Patients With Human Epidermal Growth Factor Receptor 2-Negative Primary Breast Cancer Clin Nucl Med. 2017 Dec; 42(12):912-917. . View in PubMed
  • Specialized second-opinion radiology review of PET/CT examinations for patients with diffuse large B-cell lymphoma impacts patient care and management Medicine (Baltimore). 2017 Dec; 96(51):e9411. . View in PubMed
  • Pathologically Benign Lymph Nodes Can Mimic Malignancy on Imaging in Patients With Angiomatoid Fibrous Histiocytoma Clin Orthop Relat Res. 2017 Sep; 475(9):2274-2279. . View in PubMed
  • 18F-FDG-PET/CT for systemic staging of patients with newly diagnosed ER-positive and HER2-positive breast cancer Eur J Nucl Med Mol Imaging. 2017 Aug; 44(9):1420-1427. . View in PubMed
  • Comparison of FDG-PET/CT and contrast-enhanced CT for monitoring therapy response in patients with metastatic breast cancer Eur J Nucl Med Mol Imaging. 2017 Aug; 44(9):1428-1437. . View in PubMed
  • Human Epidermal Growth Factor Receptor 2-Targeted PET/Single- Photon Emission Computed Tomography Imaging of Breast Cancer: Noninvasive Measurement of a Biomarker Integral to Tumor Treatment and Prognosis PET Clin. 2017 Jul; 12(3):269-288. . View in PubMed
  • 18F-Fluoroestradiol PET/CT Measurement of Estrogen Receptor Suppression during a Phase I Trial of the Novel Estrogen Receptor-Targeted Therapeutic GDC-0810: Using an Imaging Biomarker to Guide Drug Dosage in Subsequent Trials Clin Cancer Res. 2017 Jun 15; 23(12):3053-3060. . View in PubMed
  • Transient Osteoporosis of the Hip on FDG PET/CT Clin Nucl Med. 2017 May; 42(5):401-402. . View in PubMed
  • Value of second-opinion review of outside institution PET-CT examinations Nucl Med Commun. 2017 Apr; 38(4):306-311. . View in PubMed
  • FDG PET/CT Assesses the Risk of Femoral Pathological Fractures in Patients With Metastatic Breast Cancer Clin Nucl Med. 2017 Apr; 42(4):264-270. . View in PubMed
  • David Versus the Goliaths for the Detection of Bone Metastases J Nucl Med. 2017 11; 58(11):1776-1777. . View in PubMed
  • Prospective Clinical Trial of 18F-Fluciclovine PET/CT for Determining the Response to Neoadjuvant Therapy in Invasive Ductal and Invasive Lobular Breast Cancers J Nucl Med. 2017 07; 58(7):1037-1042. . View in PubMed
  • High prevalence of myeloid neoplasms in adults with non-Langerhans cell histiocytosis Blood. 2017 08 24; 130(8):1007-1013. . View in PubMed
  • “Comment on Hatzoglou et al: Dynamic contrast-enhanced MRI perfusion vs 18FDG PET/CT in differentiating brain tumor progression from radiation injury”-Reply. Neuro Oncol. 2017 02 01; 19(2):301-302. . View in PubMed
  • FDG-Avid Intrathecal Inflammation Following Administration of Intrathecal Methotrexate Clin Nucl Med. 2016 Dec; 41(12):995-997. . View in PubMed
  • Detection of HER2-Positive Metastases in Patients with HER2-Negative Primary Breast Cancer Using 89Zr-Trastuzumab PET/CT J Nucl Med. 2016 Oct; 57(10):1523-1528. . View in PubMed
  • (18)F-FDG-PET/CT for systemic staging of newly diagnosed triple-negative breast cancer Eur J Nucl Med Mol Imaging. 2016 Oct; 43(11):1937-44. . View in PubMed
  • Unilateral Suppression of Brown Fat on FDG PET/CT in Horner Syndrome Clin Nucl Med. 2016 Oct; 41(10):797-8. . View in PubMed
  • Initial Results of a Prospective Clinical Trial of 18F-Fluciclovine PET/CT in Newly Diagnosed Invasive Ductal and Invasive Lobular Breast Cancers J Nucl Med. 2016 Sep; 57(9):1350-6. . View in PubMed
  • Metabolic tumor volume and total lesion glycolysis on FDG-PET/CT can predict overall survival after (90)Y radioembolization of colorectal liver metastases: A comparison with SUVmax, SUVpeak, and RECIST 10. Eur J Radiol. 2016 Jun; 85(6):1224-31. . View in PubMed
  • Molecular Imaging of Biomarkers in Breast Cancer J Nucl Med. 2016 Feb; 57 Suppl 1:53S-9S. . View in PubMed
  • The Impact That Number of Analyzed Metastatic Breast Cancer Lesions Has on Response Assessment by 18F-FDG PET/CT Using PERCIST J Nucl Med. 2016 07; 57(7):1102-4. . View in PubMed
  • A prospective trial of dynamic contrast-enhanced MRI perfusion and fluorine-18 FDG PET-CT in differentiating brain tumor progression from radiation injury after cranial irradiation Neuro Oncol. 2016 06; 18(6):873-80. . View in PubMed
  • Prognostic value of FDG PET/CT-based metabolic tumor volumes in metastatic triple negative breast cancer patients Am J Nucl Med Mol Imaging. 2016; 6(2):120-7. . View in PubMed
  • Comparison of 18F-FDG PET/CT for Systemic Staging of Newly Diagnosed Invasive Lobular Carcinoma Versus Invasive Ductal Carcinoma J Nucl Med. 2015 Nov; 56(11):1674-80. . View in PubMed
  • Prognostic Value of FDG PET/CT before Allogeneic and Autologous Stem Cell Transplantation for Aggressive Lymphoma Radiology. 2015 Nov; 277(2):518-26. . View in PubMed
  • Appearance of untreated bone metastases from breast cancer on FDG PET/CT: importance of histologic subtype Eur J Nucl Med Mol Imaging. 2015 Oct; 42(11):1666-1673. . View in PubMed
  • Detection of Internal Mammary Adenopathy in Patients With Breast Cancer by PET/CT and MRI AJR Am J Roentgenol. 2015 Oct; 205(4):899-904. . View in PubMed
  • Predictive Value of Positron Emission Tomography/Computed Tomography to Assess Early Treatment Response to Dual Human Epidermal Growth Factor Receptor 2 (HER2) Blockade Without Chemotherapy for HER2-Positive Metastatic Breast Cancer: Are We Ready to Embrace This “Early Metabolic Look” Strategy? J Clin Oncol. 2015 Aug 20; 33(24):2591-3.. View in PubMed
  • Reply: Breast Cancer Staging: To Which Women Should 18F-FDG PET/CT Be Offered? J Nucl Med. 2015 Aug; 56(8):1293-4.. View in PubMed
  • Prognostic value of FDG-PET prior to autologous stem cell transplantation for relapsed and refractory diffuse large B-cell lymphoma Blood. 2015 Apr 16; 125(16):2579-81. . View in PubMed
  • Retrospective analysis of 18F-FDG PET/CT for staging asymptomatic breast cancer patients younger than 40 years J Nucl Med. 2014 Oct; 55(10):1578-83. . View in PubMed
  • Is methylene diphosphonate bone scan necessary for initial staging of Ewing sarcoma if 18F-FDG PET/CT is performed? AJR Am J Roentgenol. 2014 Apr; 202(4):859-67.. View in PubMed
  • FDG PET/CT findings in a rare case of giant fibrovascular polyp of the esophagus harboring atypical lipomatous tumor/well-differentiated liposarcoma Clin Nucl Med. 2014 Mar; 39(3):288-91. . View in PubMed
  • False-Positive [18F]fluorodeoxyglucose-avid lymph nodes on positron emission tomography-computed tomography after allogeneic but not autologous stem-cell transplantation in patients with lymphoma J Clin Oncol. 2014 Jan 01; 32(1):51-6. . View in PubMed
  • Identifying and distinguishing treatment effects and complications from malignancy at FDG PET/CT Radiographics. 2013 Oct; 33(6):1817-34. . View in PubMed
  • Prognostic value of quantitative fluorodeoxyglucose measurements in newly diagnosed metastatic breast cancer Cancer Med. 2013 Oct; 2(5):725-33. . View in PubMed
  • FDG-avid venous malformation could mimic malignancy on 18F-FDG PET/CT Clin Nucl Med. 2013 Oct; 38(10):826-8. . View in PubMed
  • Breast implant foreign body reaction mimicking breast cancer recurrence on FDG PET/CT Clin Nucl Med. 2013 Jun; 38(6):480-1. . View in PubMed
  • Musculoskeletal tumors and tumor-like conditions: common and avoidable pitfalls at imaging in patients with known or suspected cancer: Part A: benign conditions that may mimic malignancy Int Orthop. 2013 May; 37(5):871-6. . View in PubMed
  • Musculoskeletal tumours and tumour-like conditions: common and avoidable pitfalls at imaging in patients with known or suspected cancer: Part B: malignant mimics of benign tumours Int Orthop. 2013 May; 37(5):877-82. . View in PubMed
  • Comparison of the effectiveness of MRI perfusion and fluorine-18 FDG PET-CT for differentiating radiation injury from viable brain tumor: a preliminary retrospective analysis with pathologic correlation in all patients Clin Imaging. 2013 May-Jun; 37(3):451-7. . View in PubMed
  • Focused regional FDG PET/CT detects more osseous metastases than does whole-body PET/CT Clin Nucl Med. 2013 Mar; 38(3):217-8. . View in PubMed
  • Hill-Sachs lesion on FDG PET/CT Clin Nucl Med. 2013 Jan; 38(1):65-6. . View in PubMed
  • Standardized uptake value by positron emission tomography/computed tomography as a prognostic variable in metastatic breast cancer Cancer. 2012 Nov 15; 118(22):5454-62. . View in PubMed
  • False-positive FDG PET/CT due to liver parenchymal injury caused by a surgical retractor Clin Nucl Med. 2012 Sep; 37(9):910-1. . View in PubMed
  • Ipilimumab-induced colitis on FDG PET/CT Clin Nucl Med. 2012 Jun; 37(6):629-30. . View in PubMed
  • FDG PET/CT demonstration of right atrium metastasis overlooked on contrast-enhanced CT Clin Nucl Med. 2011 May; 36(5):405-6. . View in PubMed
  • B-cell non-Hodgkin lymphoma: PET/CT evaluation after 90Y-ibritumomab tiuxetan radioimmunotherapy–initial experience Radiology. 2008 Mar; 246(3):895-902. . View in PubMed
  • An unsuspected MR projectile: a “wooden” chair with metal bracing J Magn Reson Imaging. 2006 May; 23(5):781-2. . View in PubMed
  • Visualization of telomerase reverse transcriptase (hTERT) promoter activity using a trimodality fusion reporter construct J Nucl Med. 2006 Feb; 47(2):270-7. . View in PubMed
  • IVF results in de novo DNA methylation and histone methylation at an Igf2-H19 imprinting epigenetic switch Mol Hum Reprod. 2005 Sep; 11(9):631-40. . View in PubMed
  • Divergent patterns of telomere maintenance mechanisms among human sarcomas: sharply contrasting prevalence of the alternative lengthening of telomeres mechanism in Ewing’s sarcomas and osteosarcomas Genes Chromosomes Cancer. 2004 Oct; 41(2):155-62. . View in PubMed
  • Telomere maintenance in clinical medicine Am J Med. 2004 Aug 15; 117(4):262-9. . View in PubMed
  • Epigenetic regulation of the taxol resistance-associated gene TRAG-3 in human tumors Cancer Genet Cytogenet. 2004 May; 151(1):1-13. . View in PubMed
  • Activating and silencing histone modifications form independent allelic switch regions in the imprinted Gnas gene Hum Mol Genet. 2004 Apr 01; 13(7):741-50. . View in PubMed
  • Epigenetic regulation of Igf2/H19 imprinting at CTCF insulator binding sites J Cell Biochem. 2003 Dec 01; 90(5):1038-55. . View in PubMed
  • The histone code regulating expression of the imprinted mouse Igf2r gene Endocrinology. 2003 Dec; 144(12):5658-70. . View in PubMed
  • CTCF binding at the insulin-like growth factor-II (IGF2)/H19 imprinting control region is insufficient to regulate IGF2/H19 expression in human tissues Endocrinology. 2003 Oct; 144(10):4420-6. . View in PubMed
  • Absence of a telomere maintenance mechanism as a favorable prognostic factor in patients with osteosarcoma Cancer Res. 2003 Apr 15; 63(8):1759-63. . View in PubMed
  • Loss of imprinting of IGF2 and H19 in osteosarcoma is accompanied by reciprocal methylation changes of a CTCF-binding site Hum Mol Genet. 2003 Mar 01; 12(5):535-49. . View in PubMed
  • Tissue-specific alternate splicing of human telomerase reverse transcriptase (hTERT) influences telomere lengths during human development Int J Cancer. 2001 Mar 01; 91(5):644-9. . View in PubMed
  • Allelic expression of the putative tumor suppressor gene p73 in human fetal tissues and tumor specimens Biochim Biophys Acta. 2000 Apr 25; 1491(1-3):49-56. . View in PubMed
  • Regulation of telomerase by alternate splicing of human telomerase reverse transcriptase (hTERT) in normal and neoplastic ovary, endometrium and myometrium Int J Cancer. 2000 Feb 01; 85(3):330-5. . View in PubMed
  • Desensitization and resensitization of lutropin receptors expressed in transfected Y-1 adrenal cells J Endocrinol. 1999 Nov; 163(2):289-97. . View in PubMed
  • Telomerase activity in human development is regulated by human telomerase reverse transcriptase (hTERT) transcription and by alternate splicing of hTERT transcripts Cancer Res. 1998 Sep 15; 58(18):4168-72. . View in PubMed
  • Developmental regulation of telomerase activity in human fetal tissues during gestation Mol Hum Reprod. 1997 Sep; 3(9):769-73. . View in PubMed